Apr 09, 2019 - Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).
Mar 28, 2019 - AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Mar 25, 2019 - Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
Mar 25, 2019 - FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.
Mar 25, 2019 - AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
Mar 25, 2019 - American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.
Mar 20, 2019 - Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Mar 13, 2019 - Key highlights of the past week are regulatory and pipeline developments.